IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31

IONIS PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$44.38+1.44 (+3.35%)

Close on Oct 19, 2026

Market cap: $7.34B
P/E (TTM): –
Dividend yield: –

IONIS PHARMACEUTICALS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	944	705	788	587	810	729	1,123	600	514	373	284	214	147	102	99	108	122	107
Cost of Revenue	16	11	9.13	14	11	12	4.38	1.82	0	0	–	–	–	–	–	–	–	–
Gross Profit	928	694	779	573	800	717	1,118	598	514	373	–	–	–	–	–	–	–	–
Research & Development	916	902	900	–	638	531	462	412	373	340	320	239	174	155	153	145	135	106
Selling, General & Admin	394	267	233	150	186	354	287	245	108	49	37	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	49	37	20	15	13	13	12	15	14
Operating Expenses	–	–	–	–	–	–	–	661	483	393	359	262	199	171	170	157	149	120
Total Costs & Expenses	1,325	1,180	1,141	998	841	901	757	661	483	–	–	–	–	–	–	–	–	–
Operating Income	-382	-475	-354	-410	-30	-172	366	-61	31	-20	-76	-48	-52	-69	-71	-48	-28	-13
Interest Expense	17	17	13	8.12	9.35	9.51	12	45	45	39	37	22	19	21	17	13	13	12
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	0	0	-1.41	-3.55	-6.88	–	–
Other Non-Operating Income	-15	1.33	14	-7.27	-9.76	-0.06	-0.69	-0.18	-3.55	0	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	2.20	0.80	0.80	2.30	1.90	1.31	6.31	0.80	1.90	1.50	–	–
Gain (Loss) on Investments	10	-2.89	-1.91	-7.33	10	17	0.19	-0.21	–	–	20	21	2.40	1.47	4.18	-0.71	2.08	-0.97
Gain (Loss) on Sale of Assets	3.99	-7.40	-17	150	0	0	–	–	–	–	–	–	–	–	–	0.07	–	–
Pretax Income	-380	-460	-334	-258	-29	-135	339	-76	-17	-57	-88	-54	-67	-75	-85	-61	-32	–
Income Tax Expense	1.79	-6.17	32	12	-0.55	345	52	-291	-5.98	2.93	0.37	-15	-5.91	-9.11	0.01	0.09	3.19	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-85	-61	-35	-15
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	186	-8.39
Net Income incl. Noncontrolling Interests	–	–	–	-270	-29	-480	287	215	-11	-60	-88	-39	-61	-65	-85	-61	151	-23
Minority Interest in Earnings	–	–	–	0	0	-35	9.12	-59	-11	0	0	–	–	–	–	–	-4.39	-4.73
Net Income	-381	-454	-366	-270	-29	-444	278	274	0.35	-60	-88	-39	-61	–	–	-61	155	-18
Net Income to Common	–	–	–	–	–	-444	281	277	19	–	–	-39	-61	-65	-85	-61	155	–
EPS (Basic)(per share)	-2.38	-3.04	-2.56	-1.90	-0.20	-3.18	2.00	2.09	0.15	-0.50	-0.74	-0.33	-0.55	-0.65	-0.85	-0.62	1.58	-0.19
EPS (Diluted)(per share)	-2.38	-3.04	-2.56	-1.90	-0.20	-3.18	1.90	2.07	0.15	-0.50	-0.74	-0.33	-0.55	-0.65	-0.85	-0.62	1.58	-0.19
Shares Outstanding (Basic, Weighted)(shares)	160	150	143	142	141	140	140	132	124	121	120	118	111	101	100	99	98	95
Shares Outstanding (Diluted, Weighted)(shares)	160	150	143	142	141	140	153	134	126	121	120	118	111	101	100	99	98	95

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 98.2%
Operating margin: -68.0%
Net margin: -64.7%
Return on equity, FY2025: -70.8%

Financial strength

Current ratio: 7.89
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 110.9%

Valuation

P/E ratio: –
Price to sales: 8.40
Price to book: 16.69
Dividend yield: –